<DOC>
	<DOCNO>NCT02150473</DOCNO>
	<brief_summary>This study aim compare longitudinally effect adalimumab plus methotrexate ( MTX ) versus MTX monotherapy cartilage GAG content , reflect Delayed Gadolinium-enhanced magnetic resonance imaging cartilage ( dGEMRIC ) index , patient early progressive rheumatoid arthritis ( RA ) , previously receive Disease modify antirheumatic drug ( DMARD ) biologic treatment .</brief_summary>
	<brief_title>The Effect Adalimumab Plus Methotrexate ( MTX ) Versus Placebo Plus MTX Cartilage ( RA ) Patients</brief_title>
	<detailed_description>Patients randomly assign either adalimumab q2w plus oral MTX qw combination therapy oral MTX qw monotherapy plus placebo subcutaneous ( SC ) q2w ration 2:1 . To maintain blinding , match placebo SC injection dispense q2w MTX monotherapy group . All subject receive open-label MTX 15 mg qw oral tablet . All subject take approximately 5 mg weekly dietary supplement oral folate throughout study day begin 48 hour ingestion oral study medication . Defined standard therapy oral folate supplementation take single dose 24-48 h MTX therapy .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Subject diagnosis early RA ( ERA ) fulfil 2010 American college rheumatology ( ACR ) criterion classification RA Disease duration le 12 month symptoms onset . Subject previous exposure systemic biologic therapy ( e.g . abatacept , tocilizumab ) include antiTumor necrosis factor ( TNF therapy ) ( e.g. , infliximab , golimumab , certolizumab pegol , etanercept ) include adalimumab .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>rheumatoid Arthritis</keyword>
</DOC>